A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors.

@article{Becker2004ATA,
  title={A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors.},
  author={F. Becker and K. Murthi and Chase C. Smith and Jon R Come and Nuria Costa-Rold{\'a}n and C. Kaufmann and U. Hanke and C. Degenhart and S. Baumann and W. Wallner and A. Huber and S. Dédier and S. Dill and David A Kinsman and M. Hediger and N. Bockovich and S. Meier-Ewert and A. Kluge and N. Kley},
  journal={Chemistry \& biology},
  year={2004},
  volume={11 2},
  pages={
          211-23
        }
}
In this study, we explored the application of a yeast three-hybrid (Y3H)-based compound/protein display system to scanning the proteome for targets of kinase inhibitors. Various known cyclin-dependent kinase (CDK) inhibitors, including purine and indenopyrazole analogs, were displayed in the form of methotrexate-based hybrid ligands and deployed in cDNA library or yeast cell array-based screening formats. For all inhibitors, known cell cycle CDKs as well as novel candidate CDK-like and/or CDK… Expand
MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.
TLDR
During the course of this study, the pyrido[2,3-d]pyrimidine PD173955, a known SRC kinase inhibitor, was identified as a potent inhibitor of several ephrin receptor tyrosine kinases, which could perhaps be exploited in the design of inhibitors for this kinase subfamily. Expand
Evaluation of kinase inhibitor selectivity by chemical proteomics.
TLDR
This review focuses on the recent advancement of chemical proteomic methods to evaluate drug selectivity in an unbiased, comprehensive way and the identification of alternative targets for preclinical or clinical drugs that can provide new insights into their cellular modes of action. Expand
Yeast two-hybrid methods and their applications in drug discovery.
TLDR
The different transcriptional Y2H methods that are directly useful to drug discovery are reviewed and should be increasingly used in the future as they continue to evolve to harness other methodological and conceptual advances. Expand
Yeast "N"-hybrid systems for protein-protein and drug-protein interaction discovery.
TLDR
A protocol for yeast three-hybrid screening of small molecules to identify their direct targets is described and described, which holds great promise for the development of drugs which interfere with protein-protein interactions and for the discovery of drug-target interactions. Expand
Chemical Dimerizers in Three-Hybrid Systems for Small Molecule-Target Protein Profiling.
TLDR
A comprehensive and critical overview of the chemical dimerizers specifically applied in both yeast and mammalian three-hybrid systems for small molecule-target protein profiling within the broader scope of target deconvolution and drug discovery is presented. Expand
Characterisation of kinase-selective inhibitors by chemical proteomics.
  • H. Daub
  • Biology, Medicine
  • Biochimica et biophysica acta
  • 2005
TLDR
Experimental strategies relying on the affinity capture of cellular targets in combination with protein identification by mass spectrometry have been established for a variety of kinase inhibitors, allowing the direct analysis ofKinase inhibitor selectivity in biological systems and leading to new insights into the cellular modes of action of Kinase-selective small molecule antagonists. Expand
A Modular Approach to Triazole-Containing Chemical Inducers of Dimerisation for Yeast Three-Hybrid Screening
TLDR
The development of a modular approach using potentially “off the shelf” synthetic components was achieved and allowed the synthesis of a family of four triazole-containing CIDs, which were compared using the Y3H approach and showed that the modular nature of the synthetic strategy may help to overcome the challenges currently encountered with CID synthesis. Expand
Synthesis and biological evaluation of functionalised tetrahydro-β-carboline analogues as inhibitors of Toxoplasma gondii invasion.
Techniques for the identification of the protein target(s) of small molecules are proving very important following an increase in the use of phenotype-based screening in chemical biology and drugExpand
The Yeast Three-Hybrid System as an Experimental Platform to Identify Proteins Interacting with Small Signaling Molecules in Plant Cells: Potential and Limitations
TLDR
The yeast three-hybrid (Y3H) technology is implemented as a general experimental platform to scan the whole Arabidopsis proteome for targets of small signaling molecules and the perspectives and limitations of the Y3H approach for identifying targets ofsmall bioactive molecules are discussed. Expand
A Small‐Molecule–Protein Interaction System with Split‐Ubiquitin as Sensor
TLDR
A novel three‐hybrid technology based on the split‐ubiquitin system for the analysis of protein–small‐molecule interactions independently of a nuclear translocation of the complex is presented. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.
TLDR
Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may lead to the development of new therapeutics. Expand
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
TLDR
2,6,9-Trisubstituted purines have various and potent biological activities, despite high concentrations of competing endogenous purine ligands in living cells. Expand
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern.
We disclose a novel series of indenopyrazole-based cyclin-dependent kinase (CDK) inhibitors. Kinetic experiments confirmed our initial molecular modeling studies that the compounds are competitiveExpand
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.
TLDR
A simple batchwise affinity chromatography approach using two purine derivatives facilitated isolation of a small set of highly purified kinases suggests that this could be a general method for identifying intracellular targets relevant to a particular class of ligands. Expand
A GAL4-based yeast three-hybrid system for the identification of small molecule-target protein interactions.
TLDR
The development of a yeast strain designed for assaying compound-protein interactions through activation of reporter gene expression that is particularly amenable for use in a screening context for novel compound- protein interactions. Expand
Drug receptor identification from multiple tissues using cellular-derived mRNA display libraries.
TLDR
This work has used mRNA display to select, based on affinity, proteins that bind to a drug of interest, and it is anticipated that mRNA display could eventually play a key role in the discovery and characterization of new drug receptor interactions. Expand
p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol
TLDR
The anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs, which highlight the potency of moderate selectivity compounds and encourage the search for new therapeutics which simultaneously target distinct but relevant pathways of cell proliferation. Expand
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
TLDR
This work represents the first successful iterative synthesis of a potent CDK inhibitor based on the structure of fully activated CDK2–cyclin A, and the potency of O6-cyclohexylmethyl-2-(4′- sulfamoylanilino)purine was both predicted and fully rationalized on the basis of protein–ligand interactions. Expand
Cyclin-dependent kinase inhibitors.
  • Y. Dai, S. Grant
  • Chemistry, Medicine
  • Current opinion in pharmacology
  • 2003
TLDR
Interest in CDK inhibitors as antineoplastic agents will continue for the foreseeable future, as efforts are underway to uncover inhibitors that selectively target specific CDKs and to develop these as a new generation of antitumour drugs. Expand
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
TLDR
The initially unexpected scope of potential applications and the large number and chemical diversity of pharmacological inhibitors of CDKs now available constitute a very encouraging stimulus to pursue the search for optimization and characterization of protein kinase inhibitors, from which the authors expect numerous therapeutic applications. Expand
...
1
2
3
4
5
...